General
ACT III: NOW THEY’RE PAYING PATIENTS TO GO TO THE FDA
Here’s the third installment of the saga about PR tactics on the “female sexual dysfunction” front as we get closer to the October 27/28 meeting on FSD and Patient-focused drug development. I (L.T.) first wrote […]
NOW THAT THE ICE HAS MELTED, WHAT’S NEXT FOR ALS?
This summer we saw the ultimate game of truth and dare play out over social media with the ALS Ice Bucket Challenge. All over the world ordinary people as well as celebrities, billionaires, professional athletes, police […]
SUBTLETIES OF PLACEBO
Placebo response levels in many drug trials are high, especially with therapeutic areas that rely on patient-reported outcome measures. I (LT) recently read a very thoughtful paper by sexologist Andrea Bradford called “Listening to placebo […]
NOT ALL “PATIENTS” ARE CREATED EQUAL
Recently I (KW) was reminded again that not all “patient” voices are treated equally. All one has to do is look at two Congressional hearings held in Washington DC last month to see how different […]
“EVEN THE SCORE” STEPS OVER THE LINE
I (L.T.) wrote here in April about the behind-the-scenes tactics of Sprout Pharmaceuticals in pre-approval maneuvering on behalf of its drug for women’s low sexual desire, flibanserin. Well, wouldn’t you k now that just as the […]
“RIGHT TO TRY” LAWS – BOON FOR DESPERATE PATIENTS OR CRUEL TRICK?
Colorado has recently signed the first “Right to Try” law allowing patients with terminal diagnoses who are out of medical options to apply directly to companies to try drugs that are in development but which have […]
ANTIDEPRESSANT BLACKBOX WARNINGS UNDER ATTACK AGAIN
Its hard to believe that it has been almost ten years since black box warnings were added to antidepressants. These warnings came 13 years after the FDA first held hearings on link between Prozac and suicide […]
